178 related articles for article (PubMed ID: 8422185)
1. [New anthracyclines].
Ogawa M; Ariyoshi Y
Gan To Kagaku Ryoho; 1993 Jan; 20(1):27-33. PubMed ID: 8422185
[TBL] [Abstract][Full Text] [Related]
2. Clinical assessment of the structure-activity relationship of anthracyclines and related synthetic derivatives.
Young CW; Raymond V
Cancer Treat Rep; 1986 Jan; 70(1):51-63. PubMed ID: 2935251
[No Abstract] [Full Text] [Related]
3. [New anthracycline analogues in the treatment of lung cancer].
Ueoka H; Ohnoshi T; Kimura I
Gan To Kagaku Ryoho; 1992 Nov; 19(13):2146-9. PubMed ID: 1332624
[TBL] [Abstract][Full Text] [Related]
4. Phase I and II agents in cancer therapy: I. Anthracyclines and related compounds.
Wadler S; Fuks JZ; Wiernik PH
J Clin Pharmacol; 1986; 26(7):491-509. PubMed ID: 2944917
[TBL] [Abstract][Full Text] [Related]
5. A prospective randomized trial of KRN8602 and cytosine arabinoside vs. daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. The KRN8602 Leukemia Study Group.
Takemoto Y; Sampi K; Kuraishi Y; Okabe K; Tamura K; Mizoguchi H; Saito H; Masaoka T; Ogawa M
Int J Hematol; 1999 Jul; 70(1):20-5. PubMed ID: 10446490
[TBL] [Abstract][Full Text] [Related]
6. Clinical studies with new anthracyclines: epirubicin, idarubicin, esorubicin.
Hurteloup P; Ganzina F
Drugs Exp Clin Res; 1986; 12(1-3):233-46. PubMed ID: 3525075
[TBL] [Abstract][Full Text] [Related]
7. New anthracycline antitumor antibiotics.
Muggia FM; Green MD
Crit Rev Oncol Hematol; 1991; 11(1):43-64. PubMed ID: 1831987
[TBL] [Abstract][Full Text] [Related]
8. [Current status of clinical results of new antitumor drugs].
Ogawa M
Gan To Kagaku Ryoho; 1985 Feb; 12(2):179-88. PubMed ID: 3918502
[TBL] [Abstract][Full Text] [Related]
9. Activity of anthracyclines against an adriamycin (NSC-123127)-resistant subline of P388 leukemia with special emphasis on cinerubin A (NSC-18334).
Johnson RK; Ovejera AA; Goldin A
Cancer Treat Rep; 1976 Jan; 60(1):99-102. PubMed ID: 826316
[No Abstract] [Full Text] [Related]
10. Anthrapyrazoles: true successors to the anthracyclines?
Judson IR
Anticancer Drugs; 1991 Jun; 2(3):223-31. PubMed ID: 1802016
[TBL] [Abstract][Full Text] [Related]
11. [Phase I clinical study of MX2 (KRN 8602)].
Majima H
Gan To Kagaku Ryoho; 1990 Mar; 17(3 Pt 1):359-64. PubMed ID: 2310202
[TBL] [Abstract][Full Text] [Related]
12. [Therapy of acute leukemia: contribution of the new anthracyclinic drugs].
Lambertenghi-Deliliers G; Colajori E; Annaloro C; Polli EE
Recenti Prog Med; 1985; 76(7-8):392-7. PubMed ID: 3906794
[No Abstract] [Full Text] [Related]
13. Idarubicin: a brief overview on pharmacology and clinical use.
Borchmann P; Hübel K; Schnell R; Engert A
Int J Clin Pharmacol Ther; 1997 Feb; 35(2):80-3. PubMed ID: 9147715
[TBL] [Abstract][Full Text] [Related]
14. Idarubicin v daunorubicin: preclinical and clinical pharmacokinetic studies.
Speth PA; Minderman H; Haanen C
Semin Oncol; 1989 Feb; 16(1 Suppl 2):2-9. PubMed ID: 2648580
[No Abstract] [Full Text] [Related]
15. [Antitumor candidate compounds under clinical trials in Japan].
Tsukagoshi S
Gan To Kagaku Ryoho; 1990 Mar; 17(3 Pt 1):342-51. PubMed ID: 1689987
[TBL] [Abstract][Full Text] [Related]
16. [Early phase II study of KRN8602 (MX2), a novel anthracycline derivative for acute leukemia].
Takemoto Y; Sampi K; Kuraishi Y; Toki H; Tamura K; Ogawa M
Gan To Kagaku Ryoho; 1998 Dec; 25(14):2243-8. PubMed ID: 9881081
[TBL] [Abstract][Full Text] [Related]
17. Activity of menogaril against various malignant lymphoma cell lines and a human lymphoma xenograft in mice.
Yoshida M; Fujioka A; Nakano K; Yuasa C; Toko T; Takeda S; Unemi N
Anticancer Res; 1996; 16(5A):2875-9. PubMed ID: 8917401
[TBL] [Abstract][Full Text] [Related]
18. Antitumor activity of menogaril alone, and in combination against human mammary cancer models in mice and rats.
Yoshida M; Fujioka A; Nakano K; Kobunai T; Saito H; Toko T; Takeda S; Unemi N
Anticancer Res; 1996; 16(3A):1155-9. PubMed ID: 8702227
[TBL] [Abstract][Full Text] [Related]
19. A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia. AML Collaborative Group.
Br J Haematol; 1998 Oct; 103(1):100-9. PubMed ID: 9792296
[TBL] [Abstract][Full Text] [Related]
20. [Clinical pharmacology of idarubicin].
Robak T
Acta Haematol Pol; 1993; 24(4):315-26. PubMed ID: 8303977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
